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Innovations
Quorex Pharmaceuticals, Inc.
Taking the Bull by the Horns
trademarked technology based on a ing” of the bacteria at high concen-
trations is referred to as quorumseries of proprietary algorithms that
allow recognition and annotation of sensing. Bassler and her colleague
Antibiotic resistance has been a
steadily growing crisis for decades.
Antibiotic-insensitive strains of bac-
teria were seen as early as 1945, just unknown genes and three-dimen- Michael Surette subsequently showed
that upwards of 30 bacteria producetwo years after drug companies sional modeling and functional anal-
ysis of the proteins they encode. Bystarted mass producing penicillin. an autoinducer identical or highly
similar to V. harveyi’s AI-2. This listSince the early 1990s, there have coupling the capabilities of Protein
Vision with the company’s estab-been several reports of bacteria in included the clinically pathogenic
bacteria such as Escherichia coli,patient samples that resist all antibi- lished structure-based Accelerated
Drug Discovery System (ADDS),otic drugs available. Salmonella typhimurium, and Staphy-
lococcus aureus. Bassler shared the“There’s no way around the fact Quorex has an efficient and rapid
approach to identifying novel tar-that bacterium exposed to any drug, finding of AI-2 with her friend and
former colleague Jeffrey Stein, whoif it slows their replication or impairs gets and synthesizing inhibitors with
improved potency and selectivity.their survival, will develop resis- then turned this discovery into the
start-up platform for a company. Intance,” states Jeffrey L. Stein, Ph.D.,
Executive Vice President and Co- order to avoid blurring the bound-
aries between her academic pur-founder of Quorex Pharmaceuticals, “One way that we canInc. He continues, “One way that we suits and the pursuits of Quorex
slow [a microbe’s] abilitycan slow [a microbe’s] ability to de- Pharmaceuticals, Bassler decided not
to have a role in the company, asidevelop resistance is to come up with to develop resistance is
completely novel molecules that from serving as scientific advisor.to come up with com-they have not seen before.” Quorex is a small biotech of 48
pletely novel moleculesA potential weakness of antibiot- employees and since 1999 has pro-
gressed in tackling the universallyics as a general class of therapeutics that they have not seen
is that almost all of those currently enormous antibiotic problem. “Of allbefore.”available are natural products or semi- the therapeutic areas, the highest
–Jeffrey L. Stein, Ph.D.synthetic derivatives of natural prod- failure rate is in antiinfectives in the
discovery phase,” claims Stein. Thisucts. While that may not seem prob- Executive V.P. and Co-
lematic, it is. For example, penicillin is because the research demandsfounder, Quorex Pharma-is extracted from the soil microbe the discovery of a single inhibitory
ceuticals, Inc.Penicillium, which secretes penicil- molecule to target slightly different
lin in order to eliminate competing versions of a target—a single antibi-
microbes. Penicillium has coexisted otic for a spectrum of bacteria. The
Quorex was initially incorporatedand coevolved with other microbes pursuit of a new generation of antibi-
as Quorum Pharmaceuticals in Feb-in the environment, allowing for neigh- otics has been ongoing. Many large
ruary of 1999 and opened its labora-boring microbes to acquire resis- pharmaceuticals have discontinued
tories in San Diego, California latertance to its penicillin. At the time of this area of research due to failures
that year. Cofounders Jeffrey Stein,its discovery, clinically pathogenic in finding the elusive novel molecule
Ph.D. and Robert L. Robb startedbacteria were penicillin sensitive, but capable of inhibiting a highly con-
their antiinfective company basedgiven that a resistance mechanism served broad-spectrum target. This
on the discovery of the autoinducer-2against penicillin already existed in is how Quorex surmised that shut-
(AI-2) pathway first identified in Vib-nature, it was only a matter of time ting down the conserved AI-2 quo-
rio harveyi by Bonnie Bassler, Ph.D.before the infectious microbes ac- rum sensing mechanism found in
at Princeton. Bassler showed thatquired the mechanism as well. several species of bacteria could
the AI-2 molecule is secreted out ofThe current approach at Quorex prove successful. Unfortunately,
the cell, and at low cell densities thisPharmaceuticals, Inc. is to develop AI-2 is not essential for bacterial
compound produces no detectablenovel molecules that, unlike penicil- growth. Thus, any inhibitor of AI-2
effect. However, at high cell densi-lin and most other antiinfectives, are would potentially shut down the ex-
ties the secreted AI-2 molecule isnot found in nature and can specifi- pression of the pathogenic genes,
but it would not kill the bacteria. Thecally bind to a highly conserved ac- subsequently taken up by a neigh-
boring cell, in which it acts as a tran-tive site of an essential target in a end result would be a bacteriostatic
antibiotic rather than one that is bac-broad spectrum of bacteria and scription factor, upregulating patho-
genic genes such as the proteasesfungi. In the fall of 2002, Quorex ac- teriocidal. Bacteriostatic antibiotics,
such as tetracyclines (includingquired the bioinformatics company and elastases characteristic of bacte-
rial infections. This apparent “sens-Protein Vision, Inc. Protein Vision has doxycycline and minocycline) and
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erythromycins (including Biaxin and biosynthesis in bacteria; and (3) the chial and has the potential of limiting
the effectiveness of future antibiot-Azithromycin), keep bacteria from DNA ligase subunit A, which is es-
sential for bacterial transcription.multiplying but do not remove the ics. As Stein points out, “Quorex is
amongst the first companies toinvading bacteria. These bacterio- Interestingly, the currently pre-
scribed Ciprofloxacin targets thestatic agents can work with good ef- apply modern structure-based ap-
proaches to antibacterial drug dis-ficacy for an infected patient with a DNA gyrase A subunit. Ciprofloxa-
cin, which gained widespread pub-strong immune system. However, covery.” It if was an easy drug dis-
covery, clearly it wouldn’t havefor an immune-deficient patient or licity as the antianthrax drug, carries
a $6.5 billion market as the fifth gen-one with a high degree of infection, a taken so long for this obvious ap-
proach to be implemented. One canbacteriocidal antibiotic is preferred. eration of the fluoroquinolone antibi-
otics. The fluoroquinolones haveAs a small company wanting to se- hope Quorex will find continued
success.cure itself for the long term, Quorex proven to be quite successful
against gram-negative bacterial in-decided to aggressively pursue a
Chemistry & Biology invites yourbacteriocidal antibiotic. fections with poor coverage of
comments on this topic. PleaseThus, the AI-2 research is put on gram-positive pathogens. Unfortu-
write to the editors at chembiol@hold with the hope of a future return, nately, Ciprofloxacin resistance ex-
cell.com.and Quorex is currently focusing on ists, and in time its currently ob-
served efficacy will wane.the small molecule design for iso- Nicole Ballew is a freelance science writer
lated targets found in a spectrum of As with most other antibiotics, the based in Lebanon, NH (nballew@hotmail.
com).bacteria. Using the Protein Vision fluoroquinolones were derived from
nature. They were found to havetechnology, Quorex researchers
have isolated gene targets found in antiinfective effects and were sub-
sequently prescribed before thethe nosocomial (hospital-acquired)
bacteria, including at least the drug- mechanism of action was known.
Therefore, if Quorex can design anresistant forms of the gram-positive
Staphylococcus aureus, Strepto- inhibitor to a similar yet novel target
site, DNA gyrase subunit B, using acoccus, Enterococcus, and the
gram-negative Pseudomonas aeru- more highly conserved target found
in a broader spectrum of bacteria,ginosa. Once a conserved target is
found in all of these strains, Quorex an antibiotic can be rendered that
has never stimulated a resistanceexamines the detailed three-dimen-
sional structure using homology mechanism in nature prior to its dis-
tribution. Quorex’s theory is that thismodeling and protein folding predic-
tions to ensure that these conserved approach may engender a new class
of antibiotics.targets by amino acid analysis are
also conserved in the physical struc- The broad-spectrum antibiotic
candidate against DNA gyrase B isture of the binding site. The inhibi-
tors will be synthesized to bind to currently in animal studies, which
are expected to be complete by latespecific amino acid side chains;
however, for proper efficacy the side 2003. The fabH and the DNA ligase
A candidates are following closelychains must be similarly exposed in
all bacteria for binding to occur. behind the first. While the three
phases of FDA clinical trials still re-Out of the thousands of potential
targets rendered using the genomic main before any are marketable, ani-
mal studies for antibiotics are highlysearch capabilities of Protein Vision,
Quorex narrowed the list to approxi- predictive of clinical trials. This is
due to the fact that these antiinfec-mately 24 potential targets that
seemed amenable to a drug discov- tives are targeting bacteria whether
they are harbored in animals or hu-ery effort. This list of 24 was then
prioritized based on evidence from mans. With a potential for FDA fast
track status, successful animal dataprevious studies. Those targets that
had previously qualified as good could transition quickly into phase I
trials by early 2004.candidates were pursued first. Cur-
rently, Quorex is actively pursuing It may seem perplexing that the
design of a compound that specifi-novel inhibitory molecules to the fol-
lowing three key targets: (1) the DNA cally binds to conserved bacterial
residues is an approach that wasgyrase subunit B, which dimerizes
with subunit A to catalyze DNA su- only adopted in the last few years.
Amazingly, most antibiotic discover-percoiling required for bacterial
transcription; (2) the fabH gene en- ies have happened serendipitously
from natural compounds. While thiscoding a ketoacyl synthase III that
is essential to and is proposed to be has proven to be effective, this
method of discovery is rather paro-responsible for initiation of fatty acid
